VJHemOnc Podcast

Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more

Apr 17, 2025
Join Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital in Paris, as he dives into the latest advancements in preventing and managing graft-versus-host disease (GvHD). Learn about innovative therapies like Belumazidil and the complexities of CMV and HHV-6 infections after stem cell transplants. The discussion also highlights the potential of artificial intelligence in hematology, advocating for its role as a supportive tool for clinicians while ensuring compassionate patient care. It's a deep dive into the future of hematologic treatment!
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Advances in GvHD Treatment

  • Post-transplant cyclophosphamide and ATG combinations reduce graft-versus-host disease incidence effectively.
  • New treatments like fecal microbiota and Belumosidil show promise, improving outcomes and safety in resistant GVHD cases.
INSIGHT

PTCY Outperforms ATG in GVHD Prevention

  • Post-transplant cyclophosphamide (PTCY) excels over ATG in reducing severe acute and chronic GVHD, especially in unrelated donor transplants.
  • Combining lower doses of PTCY and ATG may enhance efficacy and reduce toxicity, pending further trials.
INSIGHT

Progress in CMV Management

  • CMV remains an important transplant complication but is better controlled than decades ago.
  • New ECIL guidelines advance diagnosis, prevention, and treatment, with Letermovir soon approved for pediatric use in the EU.
Get the Snipd Podcast app to discover more snips from this episode
Get the app